T cell receptor V beta 6 chain complementarity-determining region 2 (TCRVβ6 CDR2)

The **T cell receptor V beta 6 chain, complementarity-determining region 2 (CDR2)** is a structural loop within the variable domain of the β chain of the T cell receptor (TCR), specifically in the Vβ6 gene subfamily. This region, like other CDR2 loops, is encoded within the V gene segment and is critical for recognition of the MHC molecule during TCR-antigen interactions. In αβ TCRs, the CDR2 regions of both α and β chains typically make contact with conserved elements of the MHC, rather than the presented peptide, thereby contributing to MHC restriction and T cell specificity[1][3][5][7]. The CDR2 sequence is not, on its own, the focus of therapeutic targeting or biomarker development, but TCRs utilizing Vβ6 (and thus encoding this CDR2) can be targeted in certain immunotherapeutic approaches, such as selective T cell expansion for cancer immunotherapy[4]. If the interest is in the full functional receptor, the complete target would be "T cell receptor (TCR)", particularly the "T cell receptor V beta 6 chain" for family-level Vβ6 selectivity. The "CDR2" designation is too specific and refers to just one hypervariable loop (of three) within the variable region of a TCR β chain; it is not a druggable target or a canonical molecule on its own. For therapeutic research, engineered agents (such as STAR0602) have been developed to target Vβ6- and Vβ10-expressing T cells, but not the CDR2 loop alone[4]. The CDR2 loop is structurally and functionally important within the TCR, particularly for MHC contact, but is not independently targeted in current translational medicine.

Other names

TCR Vβ6 CDR2TCR β chain, CDR2 loop, Vβ6 familyCDR2β of TCRVβ6

Not applicable for CDR2 loop as a drug target alone. For Vβ6 family targeting: antibody or fusion protein binding to the Vβ6 region, modulating or expanding T cell populations